about
Targeting hypoxic response for cancer therapyThe cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysisPrinciples of targeting endothelial cell metabolism to treat angiogenesis and endothelial cell dysfunction in diseaseReceptor tyrosine kinase-mediated angiogenesisTargeting angiogenesis in small cell lung cancerCabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experienceMechanisms of vascularization in murine models of primary and metastatic tumor growthNormalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.Liquid chromatography-tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma.Personalising and targeting antiangiogenic resistance: a complex and multifactorial approach.Microenvironmental regulation of therapeutic response in cancerThe characterization of a novel monoclonal antibody against CD93 unveils a new antiangiogenic target.A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth.Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy.Endothelial cell metabolism: parallels and divergences with cancer cell metabolismAntitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer modelsPharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Microenvironmental induced essentiality of autophagyCombination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma modelsVascular endothelial growth factor receptor 3 signaling contributes to angioobliterative pulmonary hypertensionAnti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.Building better monoclonal antibody-based therapeutics.The role of photodynamic therapy in overcoming cancer drug resistance.Characterization of Pharmaceutical IgG and Biosimilars Using Miniaturized Platforms and LC-MS/MS.Association of Angiopoietin-2 and Ki-67 Expression with Vascular Density and Sunitinib Response in Metastatic Renal Cell Carcinoma.Suppression of β3-integrin in mice triggers a neuropilin-1-dependent change in focal adhesion remodelling that can be targeted to block pathological angiogenesisImproving vascular maturation using noncoding RNAs increases antitumor effect of chemotherapyImpact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer.Essential role for endocytosis in the growth factor-stimulated activation of ERK1/2 in endothelial cells.A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways.In vitro and in vivo antiangiogenic activity of desacetylvinblastine monohydrazide through inhibition of VEGFR2 and Axl pathwaysTargeting Metabolic Symbiosis to Overcome Resistance to Anti-angiogenic Therapy.Aberrant NRP-1 expression serves as predicator of metastatic endometrial and lung cancers.Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients.EphrinB2 repression through ZEB2 mediates tumour invasion and anti-angiogenic resistance.Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy.
P2860
Q26767351-EEE4BCAB-AAD5-4A23-9223-2F5C550DE488Q26796921-13BE4B43-B94B-43AE-8C17-C448E65748E0Q26859449-FD8C3BB1-649F-4A96-AB91-29409875BF5EQ27001612-D08E78F8-9C06-44FF-90E0-7A4BBEE8B3A7Q28068385-69B234A8-0E9D-42F7-A91F-883A37B27EC9Q28072166-6FBDC7D2-41C3-46CE-9110-DC9CB5336FF7Q28077790-8723BC81-80FA-4412-9988-D6156EAA40FEQ30542073-08B8B132-2BD9-41FC-9EF5-4DB4EC8D11FFQ31153869-CE0F8C97-2C96-4FDE-B044-98E9F1AC5452Q33639714-C1950B2B-A685-4CC6-8A76-AB4F249FC2F2Q33654609-3B8AB8C2-C0E1-4F8D-99D9-99DF2553C554Q33757101-6323BE50-3AAF-43C7-998C-3366390F9677Q33877489-19E12824-244C-4C7C-A700-F425843629D9Q34144848-0A2539AE-63F4-45AC-A858-26802CE13710Q34227712-F7AE0939-2A22-4928-BB22-A56D162C6BE8Q34228247-1CF194B8-AF78-4585-93C8-3322938761EDQ34253418-FB4A98CA-763B-494B-8605-8A2DB70D02ACQ34468729-B8806EB3-2DB3-4E62-9DDD-EF2572C20D49Q34589869-FAF1F97A-406C-47CA-840B-E2B943BA0255Q34978329-B62CEC29-C911-4271-9F6B-9A6A97737C43Q35517559-5BA9D42E-29CA-43AF-884D-3F0FD0DAC573Q35798947-2AC00D6F-F59B-4151-81FE-7CEFFDEADE05Q35817552-A0D7D17A-F2EE-4E2A-A0D2-9E82935808E0Q35904547-02EB6920-A337-4F13-8157-4A448B536220Q35975965-BB342CEB-90CA-462C-8D42-C17E2EC524CBQ35995721-672D6F5A-6AC0-4315-A4C9-4F2DBC99ED91Q36090830-E48903EB-3A63-40E3-BAAE-872BF8F74453Q36173653-7DEE2BB2-7CFB-4965-A133-56D6F888DC89Q36284625-24F32D49-86F2-4296-B2F1-B930AA9DA6EBQ36358324-DEDDC7BE-446A-4CFB-95AA-AC5A020D4CEDQ36428702-6E4BA2FF-EBE6-4E7E-B005-7ABF2D556E5BQ36436763-11B5A3F2-800B-4758-AC64-84CEA725B90DQ36685121-69424854-FE28-450F-AB41-22A27C778CFDQ36767541-89583EC3-F70F-4395-AE98-1D99ABDB2CAAQ36879511-B59F21EE-F50C-43DF-A0E0-D6AE93C5F148Q36910309-B35F15B7-6382-43D8-9D82-4F5FBE94519FQ36946683-B591EDF0-4E7E-4D06-BD02-E14967BAF7ADQ37024656-FE39FB85-D684-4563-9E9D-B2AC0F4CBA7CQ37153834-EE67FFD0-C64B-49AC-A0E8-DAD563A00899Q37185773-AE6FB174-108B-40CB-9DBC-EADE217ED96A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2012
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Controlling escape from angiogenesis inhibitors.
@en
Controlling escape from angiogenesis inhibitors.
@nl
type
label
Controlling escape from angiogenesis inhibitors.
@en
Controlling escape from angiogenesis inhibitors.
@nl
prefLabel
Controlling escape from angiogenesis inhibitors.
@en
Controlling escape from angiogenesis inhibitors.
@nl
P2860
P356
P1476
Controlling escape from angiogenesis inhibitors.
@en
P2093
Barbara Sennino
Donald M McDonald
P2860
P2888
P304
P356
10.1038/NRC3366
P407
P577
2012-10-01T00:00:00Z